Wilms' tumor gene WT1 encodes a transcription factor and plays an important role in cell growth and differentiation. The WT1 gene is highly expressed in leukemia and various types of solid tumors, whereas WT1 is a tumor marker convenient for the detection of minimal residual disease of leukemia. The WT1 gene was originally defined as a tumor suppressor gene, but we proposed that it was, on the contrary, an oncogene. Furthermore, the WT1 protein has proven to be a promising tumor-associated antigen, in which many human leukocyte antigen class I-or II-restricted WT1 epitopes have been identified. Clinical trials of WT1-targeted immunotherapy have confirmed its safety and clinical efficacy. WT1-specific cytotoxic T lymphocytes and WT1 antibodies are spontaneously induced in tumor-bearing patients, probably because of high immunogenicity of the WT1 protein. WT1-specific cytotoxic T lymphocytes make a major contribution to the graft-versus-leukemia effect after allogenic stem cell transplantation. When 75 cancer antigens including WT1 were prioritized according to several criteria such as therapeutic function and immunogenicity, WT1 was ranked as the top antigen. These findings suggest that a new era of WT1 immunotherapy is imminent.
WILMS' TUMOR GENE (WT1)
The WT1 gene was isolated as the gene responsible for a childhood renal neoplasm, Wilms' tumor, which was thought to arise as a result of inactivation of both alleles of the WT1 gene located at chromosome 11p13 (1, 2) . This gene encodes a zinc finger transcription factor that plays an important role in cell growth and differentiation (3) and its expression is restricted to a limited set of tissues, including the gonad, uterus, kidney and mesothelium, and to progenitor cells in various types of tissues (4 -6) . WT1 knock-out mice were found to have defects in the urogenital system and died on ED 13.5, probably due to heart failure (7).
HIGH EXPRESSION OF THE WT1 GENE IN LEUKEMIAS AND SOLID TUMORS
The WT1 gene is highly expressed in the majority of acute myeloid leukemias (AML) and acute lymphoid leukemias (ALL) (Fig. 1) (8 -18) . This makes WT1mRNA a tumor marker for leukemic blast cells and one leukemic cell in 100 000 normal peripheral blood mononuclear cells (PBMCs) can be detected by quantitation of WT1mRNA (WT1 assay) (10) . In chronic myelogenous leukemia (CML) (10) and myelodysplastic syndrome (MDS) (19) , WT1mRNA expression levels were seen to increase along with disease progression. The WT1 assay is currently considered to be an essential test managing acute leukemia and MDS by means of detection of minimal residual disease (MRD) of leukemia. The WT1 gene is also expressed at high levels in almost all types of solid tumors (20 -32) , with its expression level serving as a significant prognostic factor.
THE WT1 GENE PERFORMS AN ONCOGENIC RATHER THAN TUMOR SUPPRESSOR ONE FUNCTION
The WT1 gene was originally defined as a tumor suppressor gene (33 -38) , but we proposed, on the basis of the accumulating evidence, that the WT1 gene plays an oncogenic function in leukemogenesis and tumorigenesis (39) . For example, growth of WT1-expressing leukemic and solid cancer cells was inhibited by treatment with WT1 antisense oligomers (40, 41) and WT1-specific siRNA (42) . Conversely, forced expression of the WT1 gene promoted cell growth (43 -45) and motility (46) , suppressed apoptosis (47) and induced leukemia in WT1-transgenic mice (48) . WT1mRNA expression levels in human leukemic cells and human normal CD34 þ hematopoietic progenitor cells (HPCs) were comparatively determined at single-cell level by using single-cell reverse transcriptase -polymerase chain reaction methods (49) . Surprisingly, 1.2% of the CD34 þ HPCs expressed WT1mRNA at levels similar to those in leukemic cells. These results indicated that WT1-expressing CD34
þ HPCs are the normal counterparts of leukemic cells and that leukemic cells are mainly generated as a result of leukemic transformation of the WT1-expressing CD34 þ HPCs. Since it is known that progenitor cells of various types of tissues express WT1 (50), we hypothesized that WT1-expressing progenitor cells can differentiate into tissue-specific cells by down-regulation of WT1 expression, but that if this down-regulation is impaired, WT1-expressing progenitor cells continue to proliferate and transform as a result of occurrence of secondary, tertiary or further genetic events (Fig. 2) .
WT1 PROTEIN AS A TUMOR REJECTION ANTIGEN
High expression of the WT1 gene in leukemias and solid tumors indicated that the WT1 protein might be a promising tumor-associated antigen (TAA). Therefore, the murine WT1 protein-derived, MHC class I-restricted, 9-mer WT1 peptides Db126 (aa 126 -134), Db227 (aa 227 -235) and Db 235 (aa 235 -243) were tested for their ability to induce WT1-specific cytotoxic T lymphocytes (CTLs) in a mouse model (51, 52) . The immunized mice rejected the challenges with WT1-expressing leukemic cells and survived, but showed no histopathological damage of organs that physiologically expressed WT1. Gaiger et al. (53) reported that immunization with the murine MHC class I-binding WT1 peptides p136 -144, p235 -243 and p117 -139 induced WT1-specific CTLs in mice and lysed WT1-expressing tumor cells, while no evidence of autoimmune toxicity was observed. Finally, Gao et al. (54) showed that CML CD34 þ cells exposed to WT1-specific CTLs failed to develop leukemia in the recipient severe combined immunodeficiency mice, but CTL treatment did not inhibit engraftment of normal CD34
þ HPCs. These findings indicated that the WT1 protein could well be an attractive tumor rejection antigen.
IDENTIFICATION OF HUMAN WT1 PROTEIN-DERIVED CTL (HLA CLASS I) AND HELPER (CLASS II) EPITOPES
When PBMCs from HLA-A*0201-positive healthy donor were stimulated with T2 cells (HLA-A*0201-positive antigenpresenting cell line) pulsed with either HLA-A*0201-restrited 9-mer WT1 peptide Db126 (aa 126 -134) or WH186 (aa 187 -195), which were selected to have anchor motifs for the binding to HLA-A*0201 molecules, WT1 peptidespecific CTLs were induced and killed WT1-expressing leukemic cells, but not WT1-non-expressing cells, in an HLA-A*0201-restricted manner (55). Gao et al. (56) showed that P126 WT1 peptide (the same as Db126 in our study)-specific CTLs were elicited by the stimulation of PBMCs from HLA-A*0201-positive healthy donors with HLA-A*0201 stimulator cells that presented P126 WT1 peptide and that the induced CTLs killed endogenously WT1-expressing leukemic cells also in an HLA-A*0201-restiricted manner. Ohminami et al. (57) reported that the TAK-1, WT1-specific CD8 þ CTL clone, which was established by repeated stimulation of CD8 þ T cells from HLA-A2402 þ healthy donor with an HLA-A*2402-restricted 9-mer WT1 peptide (aa 235 -243, CMTWNQMNL), recognized naturally processed WT1 peptide and killed endogenously WT1-expressing leukemic cells in a WT1-specific HLA-A*2402-restricted manner. On the other hand, TAK-1 did not inhibit the colony formation of normal bone marrow (BM) cells from HLA-A*2402-positive healthy donors. erythema at the WT1 vaccine injection sites (72) , whereas severe leukocytopenia occurred as the result of only a single dose of 0.3 mg of modified WT1 peptide in both MDS patients ( Fig. 3) (73) . This severe leukocytopenia was thought to have resulted from an attack by WT1-specific CTLs against WT1-expressing transformed HPCs, from which almost all leukocytes were derived. As expected, de novo AML in complete remission with sufficient normal hematopoiesis remaining, no leukocytopenia occurred because normal HPCs were not attacked by WT1-specific CTLs. Both breast cancer patients and three of eight lung cancer patients who were WT1-vaccinated showed clinical effects such as regression of tumor masses and a decrease in tumor markers. These early clinical studies confirmed both the safety and clinical effectiveness of WT1 peptide immunotherapy for patients with adequate normal hematopoiesis and indicated the advisability of reducing the dose of WT1 peptide vaccine for patients with stem cell leukemia such as MDS and CML. In these patients, the majority of the hematopoietic cells were derived from WT1-expressing transformed HPCs and normal hematopoiesis was very poor (Fig. 4) . Mailander et al. (75) vaccinated HLA-A*-0201-positive AML patients with 30% blasts in BM with WT1 peptide (aa 126 -134) at a dose of 0.2 mg admixed with 1.0 mg of keyhole limpet hemocyanin, and injected granulocyte macrophage colony-stimulating factor at the same sites as those of the WT1 vaccine. Ten weeks after the vaccination, BM analysis showed that blasts accounted for less than 5% of cells and complete hematological remission was confirmed 16 weeks after the WT1 vaccination. GLIOBLASTOMA MULTIFORME WT1 vaccine was administered to 23 HLA-A*2404-positive patients with recurrent glioblastoma multiforme that was resistant to standard therapies (77) . The only adverse effect was again local erythema at the WT1 vaccine injection sites. Clinical response according to RECIST criteria was partial response in 2 patients (Fig. 5) , stable disease (SD) in 10 patients and progressive disease in 9 patients. Overall response and disease control rates were 9.5% and 57.1%, respectively. Median progression-free survival (PFS) time and 6-month PFS rate were 20.0 weeks and 33.3%, respectively. For two SD patients, long-term SD of more than 236 and 184 weeks, respectively, with only skin erythema at the WT1 vaccine injection sites has continued until the time of writing.
RENAL CELL CARCINOMA
In two of three HLA-A*2402-positive patients with advanced renal cell carcinoma (RCC) who were WT1-vaccinated, tumor growth was suppressed, so that clinical response was evaluated as SD (78) . Especially noteworthy is that development of new metastases was stopped for a prolonged period.
MULTIPLE MYELOMA
Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific CTLs (79) . A HLA-A*2402-positive patient with advanced therapy-resistant multiple myeloma was treated with WT1 vaccine (Figs 6 and 7) (80). Myeloma cells in BM decreased from 85% to 25%, and Table 1 ) with MDS. A single dose of WT1 vaccine rapidly induced WT1-specific CTLs (0.62% ! 6.61%) and nearly eradicated leukemic blast cells (50% ! 11%). Severe leukocytopenia, followed by sepsis overcome with administration of G-CSF and steroids. MDS, myelodysplastic syndrome; CTLs, cytotoxic T lymphocytes; G-CSF, granulocyte colony-stimulating factor; WBC, white blood cells. (72) reported that two patients with advanced breast cancer were treated with 0.3 mg of modified WT1 peptide or 1.0 mg of natural WT1 peptide, respectively, and that both patients showed the regression of metastatic tumors. The latter patient's disease was progressive with ileus due to metastatic tumors in colon before WT1 vaccination. After the second WT1 vaccination, a computed tomographic scan showed that thickening of the walls of the colon tract had significantly improved, accompanied by improved appetite, and the patient survived for 3 years and 1 month after WT1 vaccination.
INFANTILE CANCER
A 6-year-old girl with metastatic alveolar rhabdomyosarcoma persisting after conventional therapies, including operation, intensive chemo-and radiotherapies, was treated with an HLA-A*2402-restricted modified WT1 peptide (85) . After 3 months of WT1 vaccination, her bone metastasis became undetectable in association with an increase in WT1-specific CTLs. WT1 vaccination is being continued and she has survived in complete remission for more than 3 years and 5 months after the start of WT1 vaccination.
A NEW PHASE I CLINICAL STUDY FOR STEM CELL LEUKEMIA, MDS AND CML
The Phase I study demonstrated that MDS, which is a stem cell leukemia, was very sensitive to WT1 peptide vaccination, so that vaccination with the usual dose of WT1 peptide proved to be dangerous because of the rapid reduction in leukocytes derived from WT1-expressing transformed leukemic hematopoietic cells (72) . Therefore, a new Phase I study, in which the WT1 peptide dose started from 5 mg/body and reached a maximum of 50 through 15 mg/ body, was started in 2005. A 57-year-old male patient with chronic myelomonocytic leukemia was vaccinated biweekly with a very low dose of 5 mg/body of modified WT1 peptide ( Fig. 8 ) (86) . After the WT1 peptide vaccination, leukocyte and monocyte counts (13 780 and 1930/mL, respectively) gradually decreased to normal range in association with an increase in WT1-specific CTLs. This case demonstrated for the first time that vaccination with as little as 5 mg/body of WT1 peptide could induce WT1-specific immune response and the resultant clinical effect. whether IgG humoral immune response against WT1 protein were Th1-or Th2-type showed that Th1-biased humoral immune responses against WT1 protein were generated in leukemia and MDS (89). Oji et al. (90) analyzed WT1 IgG antibodies in patients with non-small cell lung cancer (NSCLC) and reported that pre-operative elevation of WT1 antibodies was significantly associated with longer diseasefree survival in NSCLC patients with Stages I -III, which suggests that WT1-specific immune response has an important role in anticancer immunity (Fig. 9) . Rezvani et al. (91) reported that WT1-specific CD8 þ T cell responses were detected in 5 of 8 CML patients, 4 of 6 AML patients and 7 of 12 healthy donors. The magnitude and extent of these CD8 þ T cell responses were greater in patients with myeloid leukemia than in healthy donors. They confirmed the presence of high-avidity T cell clones with a WT1-specific repertoire. Scheibenbogen et al. (92) found that T cells recognizing HLA-A2.1-binding epitopes from WT1 or proteinase 3 could be detected ex vivo in 5 of 15 HLA-A2-positive AML patients, thus providing the first evidence of spontaneous T cell response against defined antigens in AML patients. Finally, Gannagé et al. (93) reported that WT1, hTert, PR1 and bcr74 tetramer þ CD8 þ T cells were detected in 85%, 82%, 67% and 61% of patients.
HUMORAL AND CELLULAR IMMUNE RESPONSES IN TUMOR-BEARING PATIENTS

ASSOCIATION OF WT1-SPECIFIC CD8
1
T CELLS WITH GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION
Donor-derived CTLs that respond to tumor antigens emerge after hematopoietic stem cell transplantation (HSCT). Rezvani et al. (94) reported that responses to WT1, PR1 or BCR-ABL were observed in 9 of 14 patients with CML before HSCT and in 5 of 6 after HSCT, and that the responses were higher in patients with CML than in healthy donors and highest after HSCT. Morita et al. (95) used HLA-A*0201 tetramers to analyzed the frequency of CTLs against PR1, PRAME and WT1 after HSCT and found that 1 (1.0%), 10 (10.3%) and 39 (40.2%) of 97 samples from 35 HLA-A*02-positive patients (9 AML, 11 MDS, 2 CML, 4 ALL, 7 lymphomas and 2 RCC) were positive for PR1, PRAME and WT1, respectively. Serial analysis of WT1-specific CTLs during the clinical course after HSCT was performed for two patients with RCC and the results showed that higher positive rates of WT1-specific CTLs correlated with good clinical response. Rezvani et al. (96) analyzed absolute numbers of WT1-specific CD8 þ T cell as well as WT1mRNA levels that reflected MRD of leukemia in PB during the early phase of immune recovery after HSCT in 10 HLA-A*0201-positive ALL patients and demonstrated that the emergence of WT1-specific CD8 þ T cells was associated with a decrease in WT1mRNA levels, suggesting the presence of a WT1-driven graft-versusleukemia (GVL) effect. Loss of WT1-specific CD8 þ T cell responses was associated with reappearance of WT1mRNA, which is consistent with a molecular relapse (P , 0.001). These results support the notion of immunogenicity of WT1 after HSCT for ALL and a very high potential for WT1 vaccines to boost GVL after HSCT for ALL. Kapp et al. (97) reported that 28 patients, screened after allo-HSCT for T cell responses toward proteinase-3, WT1 and MUC1, showed a significant relationship between relapse and the absence of a TAA-specific T cell response, since only 2 of 13 (15%) patients with TAA-specific CTL relapsed, in contrast to relapse in 9 of 15 (60%) patients without TAA-specific CTL responses (P , 0.005).
DISCUSSION
The main focus of this review was on three aspects of the WT1 gene. First, the WT1 gene is highly expressed in leukemia and various types of solid tumors, thus making WT1mRNA as a useful tumor marker. For leukemia, the clinical usefulness of the WT1mRNA assay to detect MRD has now been established, and the assay is covered by public health insurance in Japan.
Second, the WT1 gene was originally defined as a tumor suppressor gene on the basis of the following findings: intragenic deletions or mutations in Wilms' tumor, germline mutation in patients with leukemic predisposition syndromes, and WT1-mediated growth suppression of Wilms' tumor cells expressing a WT1 splicing variant. On the other hand, we proposed that the WT1 had an oncogenic function rather than that of a tumor suppressor gene. The question of whether the WT1 gene is a tumor suppressor gene or an oncogene, or has a biphasic function combining the two characteristics remains an important and interesting issue to be resolved.
Third, a discussion about the potential of the WT1 protein as a cancer antigen should be of considerable interest. Many cancer antigens are relatively easy to isolate because of (98) . The selection and prioritization of these antigens were performed according to the following criteria: (i) therapeutic function, (ii) immunogenicity, (iii) role of the antigen in oncogenicity, (iv) specificity, (v) expression level and percent of antigen-positive cells, (vi) stem cell expression, (vii) number of patients with antigenpositive cancers, (viii) number of antigenic epitopes and (ix) cellular location of antigen expression. Although none of the 75 cancer antigens had all the characteristics of the ideal cancer antigen, WT1 was at the top of the ranking. This result can be expected to promote the development of WT1-targeted cancer immunotherapy.
Cancer immunotherapy is considered to be the fourth cancer therapy after the three major cancer therapies, surgery, chemotherapy and radiotherapy. It is thought that complete eradication of cancer stem cells is essential for cure of cancer and that only immunotherapy is capable of killing non-dividing, quiescent cancer stem cells. I would therefore like to put forward the strategy described in Table 2 . For maximal efficacy, immunotherapy should be started as soon as possible after the diagnosis of cancer and continued as long as possible, so that surgery, chemotherapy and radiotherapy can be performed under conditions of enhanced cancer immunity. I therefore believe that a new era of immunotherapy is imminent. It is important to make the most of the advantages of the four therapies: operation, chemotherapy, radiotherapy and immunotherapy Jpn J Clin Oncol 2010;40 (5) 385
